OptimizeRx Corp. (NASDAQ:OPRX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $11.21.
A number of analysts have recently weighed in on the stock. B. Riley Financial reaffirmed a “buy” rating and issued a $10.50 price target (down from $11.00) on shares of OptimizeRx in a research note on Thursday. Wall Street Zen downgraded OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. Stifel Nicolaus decreased their price target on OptimizeRx from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings raised OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, August 25th. Finally, Citigroup restated a “market outperform” rating on shares of OptimizeRx in a report on Tuesday, October 27th.
View Our Latest Report on OptimizeRx
Institutional Trading of OptimizeRx
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC bought a new stake in OptimizeRx during the first quarter worth approximately $85,000. Corient Private Wealth LP acquired a new stake in shares of OptimizeRx during the second quarter worth $77,000. Jump Financial LLC purchased a new stake in shares of OptimizeRx during the third quarter valued at $124,000. Cetera Investment Advisers purchased a new position in OptimizeRx in the 1st quarter worth about $173,000. Finally, State of Wyoming increased its stake in OptimizeRx by 234.6% in the 1st quarter. State of Wyoming now owns 35,251 shares of the company’s stock worth $221,000 after purchasing an additional 24,716 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors.
OptimizeRx Stock Performance
Shares of OPRX stock opened at $7.34 on Monday. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $15.59. The firm has a market capitalization of $138.29 million, a PE ratio of 29.36 and a beta of 1.20. The stock has a fifty day moving average of $8.43 and a two-hundred day moving average of $7.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.58 and a current ratio of 5.06.
OptimizeRx (NASDAQ:OPRX – Get Free Report) last issued its quarterly earnings data on Wednesday, November 11th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. The business had revenue of $21.61 million for the quarter, compared to analysts’ expectations of $21.19 million. OptimizeRx had a net margin of 5.33% and a return on equity of 9.58%. As a group, research analysts expect that OptimizeRx will post 0.49 EPS for the current year.
About OptimizeRx
OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company’s services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.
Featured Stories
- Five stocks we like better than OptimizeRx
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
